Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026

Related Experiment Video

Updated: Feb 28, 2026

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.7K

Targeting Nectin-4 in Bladder Cancer

    Cancer Discovery
    |June 22, 2017
    PubMed
    Summary

    Enfortumab vedotin shows promise for metastatic urothelial carcinoma. This antibody-drug conjugate demonstrated significant efficacy, even in patients resistant to prior treatments like chemotherapy and immunotherapy.

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Metastatic urothelial carcinoma has limited treatment options.
    • Platinum chemotherapy and immune checkpoint inhibitors are standard treatments.
    • Enfortumab vedotin targets nectin-4, a protein often overexpressed in urothelial cancer.

    Purpose of the Study:

    • To evaluate the safety and efficacy of enfortumab vedotin in patients with metastatic urothelial carcinoma.
    • To assess response rates in patients with prior disease progression.

    Main Methods:

    • Phase I clinical trial.
    • Enfortumab vedotin administered as treatment.
    • Patient population included those with metastatic urothelial carcinoma.

    More Related Videos

    3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
    09:24

    3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

    Published on: September 13, 2018

    9.5K
    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    21.8K

    Related Experiment Videos

    Last Updated: Feb 28, 2026

    Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
    06:12

    Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

    Published on: May 29, 2015

    7.7K
    3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
    09:24

    3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

    Published on: September 13, 2018

    9.5K
    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    21.8K

    Main Results:

    • Enfortumab vedotin demonstrated considerable efficacy.
    • Robust responses observed in patients with disease progression on platinum chemotherapy.
    • Significant responses noted in patients who progressed on immune checkpoint blockade.

    Conclusions:

    • Enfortumab vedotin shows significant potential as a treatment for metastatic urothelial carcinoma.
    • The drug is effective even in heavily pre-treated patient populations.
    • Further investigation in larger trials is warranted.